Horn Lars-Christian, Kafkova Simona, Leonhardt Karoline, Kellner Christin, Einenkel Jens
Division of Breast, Gynecologic & Perinatal Pathology, Institute of Trier, University of Leipzig, Leipzig, Germany.
Int J Gynecol Pathol. 2013 Jul;32(4):339-44. doi: 10.1097/PGP.0b013e31826a629b.
Recent new data in the pathogenesis of serous pelvic cancer and the introduction of serous tubal in situ carcinoma (STIC) and its precursors have raised the question that whether all primary peritoneal cancers (PPC) are in fact of tubal origin. Therefore, the present study evaluates the frequency of STIC and its precursor lesions in cases that were diagnosed as PPC using the morphologic criteria of the most recent WHO classification. The present study evaluates immunohistochemically (Ki-67 and p53 staining) the presence of STIC and its precursor lesions (p53 signature, serous tubal intraepithelial lesion [STIL]) in the completely processed Fallopian tubes of 46 consecutive PPCs. STIC was detected in 10 patients (21.7%) and p53 signature in 9 cases (19.6%). No STIL was observed. All except 1 STIC occurred at the fimbriated end of the Fallopian tube, and a bilateral involvement was detected in 2 cases. These precursor lesions were missed during the initial routine screening. Repeated staining for p53 was negative in STIC in 2 cases. STIC and p53 signature as precursor lesions of pelvic serous cancer are detected in some but not all the cases of primary serous peritoneal cancer. There might be the 2 different carcinogenetic pathways within PPC, and further studies are required to identify the source of serous cancer in cases without an STIC lesion.
浆液性盆腔癌发病机制的最新数据以及浆液性输卵管原位癌(STIC)及其前驱病变的引入,引发了一个问题,即所有原发性腹膜癌(PPC)是否实际上都起源于输卵管。因此,本研究使用最新WHO分类的形态学标准,评估了在诊断为PPC的病例中STIC及其前驱病变的发生率。本研究对46例连续的PPC完整处理的输卵管进行免疫组织化学(Ki-67和p53染色)评估,以检测STIC及其前驱病变(p53特征、浆液性输卵管上皮内病变[STIL])。在10例患者(21.7%)中检测到STIC,9例(19.6%)中检测到p53特征。未观察到STIL。除1例STIC外,所有STIC均发生在输卵管的伞端,2例检测到双侧受累。这些前驱病变在最初的常规筛查中被漏诊。2例STIC中p53重复染色为阴性。在部分而非所有原发性浆液性腹膜癌病例中检测到STIC和p53特征作为盆腔浆液性癌的前驱病变。PPC内可能存在两种不同的致癌途径,对于没有STIC病变的浆液性癌病例,需要进一步研究以确定其来源。